Age-related prognosis after acute myocardial infarction (The multicenter diltiazem postinfarction trial)

Frank I. Marcus*, Karen Friday, John McCans, Thomas Moon, Elizabeth Hahn, Leonard Cobb, Jesse Edwards, Lewis Kuller

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


The basis for the excess mortality with age after acute myocardial infarction (AMI) is not clear, nor is it known whether the mode of death is altered with age. Age-related factors predictive of mortality and age-related mechanisms of the 333 deaths were examined in 2,466 patients who were enrolled in a placebo-controlled trial to determine the effect of diltiazem on mortality and reinfarction after AMI. There were 3 age groups with increasing mortality rates: ages 25 to 49 (n = 499), 50 to 64 (n = 1,228) and 65 to 75 years (n = 739). There was a significant age-related increase in the proportion of patients with baseline risk factors. These baseline characteristics did not differ by treatment (placebo vs diltiazem). However, multi-variate survivorship analysis still identified age as an independent risk factor for cardiac death. The proportion of arrhythmic and myocardial failure deaths did not differ by treatment or age group.

Original languageEnglish (US)
Pages (from-to)559-566
Number of pages8
JournalThe American journal of cardiology
Issue number9
StatePublished - Mar 1 1990

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Age-related prognosis after acute myocardial infarction (The multicenter diltiazem postinfarction trial)'. Together they form a unique fingerprint.

Cite this